Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Epclusa 200 mg/50 mg film-coated tablets

Active Ingredient:
sofosbuvir, velpatasvir
Company:  
Gilead Sciences Ltd See contact details
ATC code: 
J05AP55
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Epclusa▼ 200 mg/50 mg film-coated tablets (sofosbuvir/velpatasvir): supply of Irish product

Gilead Sciences Ltd is currently experiencing supply disruption with Epclusa 200 mg/50 mg film-coated tablets (sofosbuvir/velpatasvir) in the UK. Gilead Sciences Ltd has obtained approval from the MHRA to supply Irish product.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Gilead Sciences Ltd
Company image
Address
280 High Holborn, London, WC1V 7EE, UK
Telephone
+44 (0)203 681 4500
E-mail
[email protected]
Medical Information Direct Line
08000 113 700 (UK)
Medical Information Direct Line
+353 214 825 999 (Ireland)
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)203 681 4681
Customer Care direct line
+353 1 291 3580 (Ireland)